374 related articles for article (PubMed ID: 19648160)
1. Galectin-3: a novel mediator of heart failure development and progression.
de Boer RA; Voors AA; Muntendam P; van Gilst WH; van Veldhuisen DJ
Eur J Heart Fail; 2009 Sep; 11(9):811-7. PubMed ID: 19648160
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.
Sharma UC; Pokharel S; van Brakel TJ; van Berlo JH; Cleutjens JP; Schroen B; André S; Crijns HJ; Gabius HJ; Maessen J; Pinto YM
Circulation; 2004 Nov; 110(19):3121-8. PubMed ID: 15520318
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure.
McCullough PA; Olobatoke A; Vanhecke TE
Rev Cardiovasc Med; 2011; 12(4):200-10. PubMed ID: 22249510
[TBL] [Abstract][Full Text] [Related]
4. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.
Christenson RH; Duh SH; Wu AH; Smith A; Abel G; deFilippi CR; Wang S; Adourian A; Adiletto C; Gardiner P
Clin Biochem; 2010 May; 43(7-8):683-90. PubMed ID: 20153309
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of galectin-3 in patients with heart failure.
Bošnjak I; Selthofer-Relatić K; Včev A
Dis Markers; 2015; 2015():690205. PubMed ID: 25960597
[TBL] [Abstract][Full Text] [Related]
6. [Galectin 3--a new biomarker for diagnostics and outcome of chronic heart failure].
Lakomkin SV; Skvortsov AA; Goriunova TV; Masenko VP; Tereshchenko SN
Kardiologiia; 2012; 52(3):45-52. PubMed ID: 22839443
[TBL] [Abstract][Full Text] [Related]
7. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation.
Beiras-Fernandez A; Weis F; Rothkopf J; Kaczmarek I; Ledderose C; Dick A; Keller T; Beiras A; Kreth S
Ann Transplant; 2013 Nov; 18():643-50. PubMed ID: 24264380
[TBL] [Abstract][Full Text] [Related]
8. Personalizing biomarker strategies in heart failure with galectin-3.
Sherwi N; Merali S; Wong K
Future Cardiol; 2012 Nov; 8(6):885-94. PubMed ID: 23176690
[TBL] [Abstract][Full Text] [Related]
9. Regulation of adverse remodelling by osteopontin in a genetic heart failure model.
Psarras S; Mavroidis M; Sanoudou D; Davos CH; Xanthou G; Varela AE; Panoutsakopoulou V; Capetanaki Y
Eur Heart J; 2012 Aug; 33(15):1954-63. PubMed ID: 21525025
[TBL] [Abstract][Full Text] [Related]
10. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 in heart failure with preserved ejection fraction.
de Boer RA; Edelmann F; Cohen-Solal A; Mamas MA; Maisel A; Pieske B
Eur J Heart Fail; 2013 Oct; 15(10):1095-101. PubMed ID: 23650131
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3.
Leone M; Iacoviello M
Minerva Cardioangiol; 2016 Apr; 64(2):181-94. PubMed ID: 26426300
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3 interferes with tissue repair and promotes cardiac dysfunction and comorbidities in a genetic heart failure model.
Vlachou F; Varela A; Stathopoulou K; Ntatsoulis K; Synolaki E; Pratsinis H; Kletsas D; Sideras P; Davos CH; Capetanaki Y; Psarras S
Cell Mol Life Sci; 2022 Apr; 79(5):250. PubMed ID: 35441327
[TBL] [Abstract][Full Text] [Related]
14. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure.
Meijers WC; van der Velde AR; de Boer RA
Expert Rev Mol Diagn; 2014 Apr; 14(3):257-66. PubMed ID: 24606321
[TBL] [Abstract][Full Text] [Related]
15. The regulation of inflammation by galectin-3.
Henderson NC; Sethi T
Immunol Rev; 2009 Jul; 230(1):160-71. PubMed ID: 19594635
[TBL] [Abstract][Full Text] [Related]
16. The role of galectin-3 in heart failure and cardiovascular disease.
Zhong X; Qian X; Chen G; Song X
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):197-203. PubMed ID: 30372548
[TBL] [Abstract][Full Text] [Related]
17. Relation of inflammatory status to major adverse cardiac events and reverse remodeling in patients undergoing cardiac resynchronization therapy.
Michelucci A; Ricciardi G; Sofi F; Gori AM; Pirolo F; Pieragnoli P; Giaccardi M; Colella A; Porciani MC; Di Biase L; Padeletti L; Abbate R; Gensini GF
J Card Fail; 2007 Apr; 13(3):207-10. PubMed ID: 17448418
[TBL] [Abstract][Full Text] [Related]
18. Fibrosis in heart failure subtypes.
Toprak G; Yüksel H; Demirpençe Ö; Islamoglu Y; Evliyaoglu O; Mete N
Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2302-9. PubMed ID: 24065222
[TBL] [Abstract][Full Text] [Related]
19. On the role of galectin-3 in cancer apoptosis.
Nakahara S; Oka N; Raz A
Apoptosis; 2005 Mar; 10(2):267-75. PubMed ID: 15843888
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive review of the prognostic value of galectin-3 in heart failure.
Coburn E; Frishman W
Cardiol Rev; 2014; 22(4):171-5. PubMed ID: 24407048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
